Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (171-180 of 304) with videos related to

Pageof 31
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|September 12, 2015
Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into PracticeDeirdre R Pachman, Kathryn Ruddy, Lindsey R Sangaralingham, et al.
Investigational New Drugs|November 20, 2015
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignanciesJoleen M Hubbard, George Kim, Mitesh J Borad, et al.
British Journal of Cancer|November 30, 2018
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancerFotios Loupakis, Herbert I Hurwitz, Leonard Saltz, et al.
Clinical Colorectal Cancer|October 12, 2016
Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal CancerBen Y Zhang, Jeremy C Jones, Andrew M Briggler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 16, 2019
Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicineJesus Vera, Jonas Paludo, Lisa Kottschade, et al.
The Oncologist|July 9, 2011
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practiceCharles D Blanke, Richard M Goldberg, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2020
A new prognostic and predictive tool for shared decision making in stage III colon cancerAlberto F Sobrero, Alberto Puccini, Qian Shi, et al.
International Journal of Statistics in Medical Research|August 10, 2019
Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance)Brittny T Major-Elechi, Paul J Novotny, Jasvinder A Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance)Charles L Loprinzi, Rui Qin, Shaker R Dakhil, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 8, 2015
MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathyCollin Zimmerman, Pamela J Atherton, Deirdre Pachman, et al.
Pageof 31

Showing results (171-180 of 304) with videos related to

Sort By:
Pageof 31
Journal of the National Comprehensive Cancer Network : JNCCN|September 12, 2015
Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into PracticeDeirdre R Pachman, Kathryn Ruddy, Lindsey R Sangaralingham, et al.
Investigational New Drugs|November 20, 2015
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignanciesJoleen M Hubbard, George Kim, Mitesh J Borad, et al.
British Journal of Cancer|November 30, 2018
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancerFotios Loupakis, Herbert I Hurwitz, Leonard Saltz, et al.
Clinical Colorectal Cancer|October 12, 2016
Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal CancerBen Y Zhang, Jeremy C Jones, Andrew M Briggler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 16, 2019
Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicineJesus Vera, Jonas Paludo, Lisa Kottschade, et al.
The Oncologist|July 9, 2011
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practiceCharles D Blanke, Richard M Goldberg, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2020
A new prognostic and predictive tool for shared decision making in stage III colon cancerAlberto F Sobrero, Alberto Puccini, Qian Shi, et al.
International Journal of Statistics in Medical Research|August 10, 2019
Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance)Brittny T Major-Elechi, Paul J Novotny, Jasvinder A Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance)Charles L Loprinzi, Rui Qin, Shaker R Dakhil, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 8, 2015
MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathyCollin Zimmerman, Pamela J Atherton, Deirdre Pachman, et al.
Pageof 31